

ii. the apparent molecular weight can be decreased to that of normal tau proteins upon treatment of said abnormally phosphorylated tau proteins with a dephosphorylating agent; and

B. the monoclonal antibody is selected to exclude forming in the immunological complex with

i. normal tau proteins;

ii. tau protein present in brain homogenates derived from the human brain, said homogenates being isolated from a patient having died of a nonneurological disorder; and

iii. the phosphorylated epitope that has been dephosphorylated with a dephosphorylating agent.

Please add new claim 30 as follows:

30. (New) A monoclonal antibody according to claim 20, wherein said monoclonal antibody forms immunological complex with phosphorylated serines present in the human abnormally phosphorylated tau protein.